458 related articles for article (PubMed ID: 10963197)
1. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.
Kahan BD
Lancet; 2000 Jul; 356(9225):194-202. PubMed ID: 10963197
[TBL] [Abstract][Full Text] [Related]
2. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.
MacDonald AS;
Transplantation; 2001 Jan; 71(2):271-80. PubMed ID: 11213073
[TBL] [Abstract][Full Text] [Related]
3. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.
Machado PG; Felipe CR; Hanzawa NM; Park SI; Garcia R; Alfieri F; Franco M; Silva HT; Medina-Pestana JO
Clin Transplant; 2004 Feb; 18(1):28-38. PubMed ID: 15108768
[TBL] [Abstract][Full Text] [Related]
4. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
[TBL] [Abstract][Full Text] [Related]
5. Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine.
Machado PG; Felipe CR; Park SI; Garcia R; Moreira S; Casarini D; Franco M; Alfieri F; Tedesco-Silva H; Medina-Pestana JO
Braz J Med Biol Res; 2004 Sep; 37(9):1303-12. PubMed ID: 15334195
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
Kahan BD; Julian BA; Pescovitz MD; Vanrenterghem Y; Neylan J
Transplantation; 1999 Nov; 68(10):1526-32. PubMed ID: 10589950
[TBL] [Abstract][Full Text] [Related]
9. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
Tsai MK; Chueh SC; Hu RH; Lee PH
J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
[TBL] [Abstract][Full Text] [Related]
10. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
[TBL] [Abstract][Full Text] [Related]
11. A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results.
Machado PG; Garcia C; Felipe CR; Garcia R; Franco M; Delcelo R; Silva HT; Medina JO
Transplant Proc; 2001; 33(1-2):1074-5. PubMed ID: 11267196
[No Abstract] [Full Text] [Related]
12. A randomized trial comparing cyclosporine and steroids with cyclosporine, azathioprine, and steroids in cadaveric renal transplantation.
Amenábar JJ; Gómez-Ullate P; García-López FJ; Aurrecoechea B; García-Erauzkin G; Lampreabe I
Transplantation; 1998 Mar; 65(5):653-61. PubMed ID: 9521199
[TBL] [Abstract][Full Text] [Related]
13. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome after switch from cyclosporine-based triple-drug immunosuppression to double therapy at three months.
Aichberger C; Eberl T; Riedmann B; Pernthaler H; Ofner D; Königsrainer A; Margreiter R
Clin Transplant; 1996 Apr; 10(2):209-12. PubMed ID: 8664521
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
Ettenger RB; Grimm EM
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
Keogh A; Richardson M; Ruygrok P; Spratt P; Galbraith A; O'Driscoll G; Macdonald P; Esmore D; Muller D; Faddy S
Circulation; 2004 Oct; 110(17):2694-700. PubMed ID: 15262845
[TBL] [Abstract][Full Text] [Related]
17. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.
Kahan BD; Kaplan B; Lorber MI; Winkler M; Cambon N; Boger RS
Transplantation; 2001 May; 71(10):1400-6. PubMed ID: 11391226
[TBL] [Abstract][Full Text] [Related]
18. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. Italian Multicentre Study Group for Renal Transplantation (SIMTRe).
Ponticelli C; Tarantino A; Segoloni GP; Cambi V; Rizzo G; Altieri P; Mastrangelo F; Castagneto M; Salvadori M; Valente U; Cossu M; Federico S; Pisani F; Montagnino G; Messina M; Arisi L; Carmellini M; Piredda G; Corbetta G
J Am Soc Nephrol; 1997 Apr; 8(4):638-46. PubMed ID: 10495794
[TBL] [Abstract][Full Text] [Related]
19. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
